Patent ID: 6221878
Filing Date: 2001-04-24
Classification: A61K

Abstract:
A method for the treatment of depression which comprises administering an effective amount of a compound which acts as an antagonist of 5-hydroxy-tryptamine (5-HT) at 5-HT.sub.3 receptors,excluding 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one, and physiologically acceptable salts and solvates thereof,and further excluding endo-N-(8-methyl-8-azabicyclo[3.2. 1]oct-3-yl)-2,3-dihydro-3,3-dimethylindole-1-carboxamide, or a physiologically acceptable salt or solvate thereof,and further excluding 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxybenzamide, or a physiologically acceptable salt or solvate thereof, and further excluding a compound of formula (I): ##STR12##whereinR.sub.1 and R.sub.2 independently represent hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, amino, C.sub.1-4 alkylamino, di(C.sub.1-4)alkylamino, mercapto or C.sub.1-4 alkylthio;R.sub.3 represents hydrogen, C.sub.1-4 alkyl, C.sub.3-5 alkenyl, aryl or aralkyl;R.sub.4 represents hydrogen, C.sub.1-7 alkyl, C.sub.3-5 alkenyl, or aralkyl;n is 2 or 3;the free valence is attached to either fused ring, and the azabicyclic ring is in either the exo or endo configuration;or an acid addition salt or quaternary ammonium salt thereof, and further excluding a compound of formula (IV): ##STR13##whereinX is CO and Y is NH or O;and p is 3 or 3;or a pharmaceutically acceptable salt thereof.